ARDX ARDELYX, INC.

Nasdaq ardelyx.com


$ 6.04 $ -0.39 (-6.07 %)    

Friday, 31-Oct-2025 11:45:21 EDT
QQQ $ 632.95 $ -1.14 (-0.18 %)
DIA $ 475.70 $ -0.19 (-0.04 %)
SPY $ 683.86 $ -1.21 (-0.18 %)
TLT $ 90.26 $ -0.30 (-0.33 %)
GLD $ 369.74 $ -0.74 (-0.2 %)
$ 5.01
$ 6.43
$ 6.04 x 655
$ 6.05 x 800
$ 5.86 - $ 6.71
$ 3.21 - $ 6.78
6,068,810
na
1.22B
$ 0.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 08-04-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-20-2025 12-31-2024 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 10-31-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 03-02-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-13-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-08-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-06-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 03-06-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-08-2018 03-31-2018 10-Q
32 03-14-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-05-2017 03-31-2017 10-Q
36 02-17-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-04-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ardelyx-q3-sales-110329m-beat-100878m-estimate

Ardelyx (NASDAQ:ARDX) reported quarterly sales of $110.329 million which beat the analyst consensus estimate of $100.878 millio...

 ardelyx-presents-data-supporting-retainagogue-ibsrela-at-acg-annual-scientific-meeting-in-phoenix

IBSRELA patients reported treatment satisfaction in real-world surveyPost-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstra...

 ardelyx-announces-it-will-present-new-data-supporting-its-kidney-disease-drug-xphozah-at-american-society-of-nephrologys-kidney-week-2025-november-59-in-houston-texas

Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovati...

 ardelyx-appoints-sue-hohenleitner-cfo-effective-nov-4

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a missi...

 piper-sandler-maintains-neutral-on-ardelyx-raises-price-target-to-9

Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Neutral and raises the price target from $8...

 wedbush-maintains-outperform-on-ardelyx-raises-price-target-to-14

Wedbush analyst Laura Chico maintains Ardelyx (NASDAQ:ARDX) with a Outperform and raises the price target from $13 to $14.

 raymond-james-maintains-outperform-on-ardelyx-raises-price-target-to-12

Raymond James analyst Ryan Deschner maintains Ardelyx (NASDAQ:ARDX) with a Outperform and raises the price target from $11 t...

 ardelyx-q2-eps-008-beats-012-estimate-sales-97662m-beat-82208m-estimate

Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 34...

 hc-wainwright--co-assumes-ardelyx-at-buy-announces-price-target-of-10

HC Wainwright & Co. analyst Matthew Caufield assumes Ardelyx (NASDAQ:ARDX) with a Buy rating and announces Price Target ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION